Skip to main content
Clinical Trials/NCT02637817
NCT02637817UnknownNot Applicable

MRI-based Biomarkers for the Prognosis Judgement of Punctate White Matter Lesions in Neonates: a Longitudinal Multicenter Study

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country600 target enrollmentStarted: January 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
600
Locations
1
Primary Endpoint
Cerebral Palsy

Study Overview

Brief Summary

As a common white matter (WM) disease in preterm neonates, punctate white matter lesion (PWML) frequently leads to the abnormalities of brain development (e.g. the motor, visual and auditory disorders), even to cerebral palsy (CP) and amblyopia during childhood. However, it is lack of certain methods in identifying the prognosis of PWML. Through using various advanced MRI techniques, neuro-behavioral and visual assessments, a multicenter longitudinal study would be conducted to follow-up the PWML neonates with varying spatial-position and degree lesions. Through tracking the variations in WM microstructures from neonate period to childhood (2 years old and 3 years old), this study aims to explore (1) the potential relations between varying PWMLs and motor and visual disorders (2) the relations between WM MRI-metrics and neurodevelopmental assessment results, and thus determine the early biomarkers to identify CP and amblyopia.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
1 Day to 28 Days (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • (1) Age: 1-28 days (2) PWML (3) High quality MRI scan

Exclusion Criteria

  • (1) Congenital malformations, infections, metabolic disorders, intraventricular hemorrhage (2) Neonates of mothers with gestational diabetes, hypertension, hypoglycemia and history of alcohol

Outcomes

Primary Outcomes

Cerebral Palsy

Time Frame: At age 2

The enrolled subjects who will be diagnosed as cerebral palsy by clinical examination at age 2.

Secondary Outcomes

  • Amblyopia or movement disorder(At age 3)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials